Can a quick phone scan really show my health risks without a doctor visit?

Consumers asked to point a phone camera at their face for 30 seconds tend to react the same way: skepticism. The request feels too easy to be real. For decades, proving you were healthy enough for life insurance meant a scheduled nurse visit, a blood draw, and a urine sample. So when an application instead asks for a brief selfie video, the natural question is whether a quick phone scan can really surface health risks without a doctor in the room. The honest answer matters to two audiences at once: the applicant deciding whether to trust the process, and the underwriting team deciding whether to trust the data. The case for remote health screening insurance workflows rests not on hype but on what the optical sensors can actually measure, and how that compares to the traditional file.

A non-contact, smartphone-based photoplethysmography app tested on 562 participants from September to November 2024 reached 99.1% accuracy for heart rate and 93.4% for blood oxygen saturation, while blood pressure estimation remained far weaker at roughly 61% for systolic readings.

What remote health screening insurance scans can and cannot measure

The technology behind a phone scan is remote photoplethysmography, or rPPG. The camera detects tiny color changes in facial skin caused by blood flowing with each heartbeat. From that signal, software estimates cardiovascular and physiological markers. This is the core of most remote health screening insurance pilots running today, and understanding its boundaries is the whole conversation.

The 2024 validation study published in PMC, led by researchers evaluating a non-contact PPG mobile application, is instructive precisely because it is not uniformly flattering. Heart rate and oxygen saturation came back strong. Blood pressure, the metric carriers most want, came back unreliable, with systolic accuracy around 61.3% and diastolic near 56.0%. Separately, Google Research validated its PHRM rPPG system between 2020 and 2024 on more than 190,000 video recordings, reporting a mean absolute percentage error of 6.09% for resting heart rate and, importantly, consistent performance below 10% error across all skin tone groups. That skin-tone result addresses one of the most-cited fairness objections to camera-based vitals.

So a phone scan does not replace a lab panel. It is not measuring cholesterol, A1C, nicotine metabolites, or kidney function. What it does well is capture a set of cardiovascular signals quickly, repeatably, and at the applicant's convenience. For underwriting, the question is not "does the scan equal blood work" but "does the scan plus structured health questions plus third-party data produce a risk picture good enough to price the policy."

Screening method	Time to complete	Marginal cost	Measures captured	Best fit
Traditional paramedical exam	2 to 4 weeks to schedule and process	$75 to $150 per applicant	Blood panel, urine, BP, height/weight, build	High face amounts, complex risk
Remote phone scan (rPPG)	30 to 60 seconds	Near zero per scan	Heart rate, HR variability, SpO2, estimated respiration	Simplified and accelerated issue
Wearable data feed	Continuous, opt-in	Device dependent	Resting HR trend, activity, sleep	Engaged, tech-forward applicants
Health questionnaire only	5 to 10 minutes	Near zero	Self-reported history	Smallest face amounts, fast triage

The table makes the trade clear. The scan is not the most comprehensive option. It is the most convenient one, and convenience is itself an underwriting variable because abandoned applications never get priced at all.

Key points an applicant should understand:

• A phone scan estimates vitals; it does not diagnose disease.
• A single elevated heart rate reading does not decide an application on its own.
• The scan is one input among health questions, prescription history, and medical-record checks.
• Results that fall outside expected ranges typically route to additional review, not automatic decline.

Industry applications

Accelerated and simplified-issue underwriting

The clearest fit is accelerated underwriting, where carriers already waive fluids for a subset of qualifying applicants. The Society of Actuaries published its 2022 Accelerated Underwriting Practices Survey in November 2023, confirming how widely fluidless paths have spread since most programs launched in 2017 and 2018. A 30-second scan adds a low-cost objective signal to programs that otherwise lean heavily on self-reported answers and database hits. It does not introduce the friction that pushed carriers toward fluidless models in the first place.

Reaching applicants the exam model misses

The paramedical exam quietly filters who buys coverage. Applicants in rural areas, shift workers, and anyone reluctant to host a stranger for a blood draw drop out at higher rates. A remote scan that completes from a couch widens the funnel. With the global life insurance market valued at roughly $3.0 trillion in 2023 and projected to grow near 9.7% annually through 2030 by Grand View Research, even small improvements in completion rates carry real premium volume.

Triage and routing

Many carriers use the scan not as a final answer but as a sorting mechanism. Clean, in-range results move to fast issue. Ambiguous results escalate. This preserves the speed advantage for the majority while reserving expensive verification for the cases that need it.

Current research and evidence

The evidence base is improving but uneven, and underwriters should hold both facts at once. On the strong side, heart rate estimation from a phone camera now rivals consumer wearables, per the Google Research PHRM validation across 2020 to 2024, with the skin-tone consistency that earlier methods lacked. On the cautious side, the 2024 PMC study shows blood pressure remains the weak link, which is why responsible programs do not present camera-derived BP as exam-equivalent.

Mortality outcomes are the real test for any underwriting change. The SOA's August 2024 work on accelerated underwriting found that a typical fluidless program can expect 10% to 15% mortality slippage relative to fully underwritten business, with term products running nearly 1.8 times higher slippage than permanent products. That figure is not an argument against digital screening; it is the benchmark any new data source must help close. The relevant question for a scan is whether adding an objective cardiovascular signal narrows that gap compared with questionnaire-only triage. Early carrier pilots suggest the value is in catching misrepresentation and adding a second objective data point, not in matching a blood panel marker for marker.

The future of remote health screening insurance

The trajectory points toward scans becoming one layer in a stacked model rather than a single hero metric. Three shifts look likely:

• Multi-signal fusion, where the scan combines with prescription history, electronic health records, and optional wearable feeds so no single input carries the decision.
• Tighter regulatory attention on transparency and bias testing, building on the skin-tone fairness work already published, which carriers will need to document.
• Better protective-value studies as fluidless programs accumulate credible mortality experience, letting actuaries price the scan's contribution with real data rather than assumptions.

The destination is not a world without medical evidence. It is a world where the level of evidence scales to the risk: a phone scan for a modest term policy, a full exam for a large permanent one, and a clear, auditable rationale for which path each applicant takes.

Frequently asked questions

Can a phone scan really detect my health risks without a doctor?

It can estimate several cardiovascular signals, such as heart rate and oxygen saturation, with accuracy that recent 2024 studies rate highly. It does not diagnose disease or replace a blood test. In insurance, it is one input combined with your health questions and other records, not a standalone medical opinion.

Is a phone scan as accurate as the nurse visit and blood work?

Not for everything. A blood panel measures things a camera cannot, like cholesterol and glucose. The phone scan trades that depth for speed and convenience, and carriers generally reserve full exams for higher face amounts or complex cases while using scans for simplified and accelerated products.

Will an abnormal scan result automatically deny my application?

Typically no. A single out-of-range reading usually routes the application to additional review rather than triggering an automatic decline. Underwriters look at the full picture, and applicants can often retry a scan if conditions during the first attempt were poor.

Why do insurers trust a 30-second scan?

Because they do not rely on it alone. The scan adds a low-cost objective data point on top of self-reported answers and third-party databases, helping flag inconsistencies and route clean applications faster. It is the combination, not the scan by itself, that supports the underwriting decision.

Circadify is building toward this stacked-evidence model for payers and insurers, pairing a fast applicant self-scan with the data integration underwriting teams actually need to act on results. Product managers and underwriting leaders evaluating where a phone scan fits in their risk stack can review demos and integration guides at circadify.com/industries/payers-insurance.